AEGEAN and Beyond: Perioperative Immunotherapy for NSCLC

Episode
186
Soundcloud
Share

Lung Cancer Considered host Dr. Narjust Florez leads an informed discussion on the AEGEAN Trial, which explored neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in patients with resected NSCLC.

Guest
Narjust Florez
Narjust Florez

MD

Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Tercia Reis
Tercia Reis

MD

Thoracic Medical Oncologist
Grupo Oncoclinicas in Salvador